ArticlePediatric nephrology (Berlin, Germany)2017
Acute kidney injury during a pediatric sickle cell vaso-occlusive pain crisis.
Article in Pediatric nephrology (Berlin, Germany), 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 3 registered trials, which are not on this map. Cited by 49 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Chronobiology and Chronopharmacology to Prevent Sickle Cell Kidney Disease
Acute Kidney Injury in Patients With Sickle Cell Disease
Ketorolac Dosing for Acute Vaso-Occlusive Crisis in Pediatric Patients With Sickle Cell Disease
Who cites it
49 citing papers in PubMed, 90 citations in OpenAlex.
- The Unfinished Story of Sickle Cell Nephropathy: A Narrative Review of Knowledge Gaps and Research Imperatives.Journal of clinical medicine · 2026Review
- Phase I study of the safety and pharmacokinetics of CSL889 (hemopexin) in adults with sickle cell anemia.Haematologica · 2026Article
- Augmenting hemopexin-mediated heme scavenging mitigates sepsis-induced acute kidney injury in humanized sickle cell mice.Blood vessels, thrombosis & hemostasis · 2026Article
- Cytochrome bBiomedicine & pharmacotherapy = Biomedecine & pharmacotherapie · 2026Article
- Acute kidney injury: incidence, risk factors, and early outcomes in hospitalized children with sickle cell disease attending a tertiary hospital in Eastern Uganda.BMC pediatrics · 2026Article
- Low bone mineral density and pain impact in adults with sickle cell disease.Blood advances · 2026Article
- The Pediatric Clinician's Approach to Acute or Chronic Neurologic Symptoms in Children with Sickle Cell Disease.Pediatric clinics of North America · 2026Review
- Management of Kidney Disease with Sickle Cell Disease.Journal of the American Society of Nephrology : JASN · 2025Review
- Nitrated fatty acids protect against acute kidney injury in sickle cell disease.Blood advances · 2025Article
- Implementing ASH's guidelines for acute medical care for incarcerated children and adults with sickle cell disease.Blood advances · 2025Article
- Hydroxyurea Mitigates Heme-Induced Inflammation and Kidney Injury in Humanized Sickle Cell Mice.International journal of molecular sciences · 2025Article
- High Creatine Kinase Levels in Viral Myositis: A Case of Rhabdomyolysis-Induced Renal Failure.The American journal of case reports · 2025Article
- Acute Kidney Injury in Children: A Focus for the General Pediatrician.Children (Basel, Switzerland) · 2024Review
- Article
- Sex-disaggregated analysis of acute kidney injury in hospitalized children with sickle cell anemia in Uganda.American journal of physiology. Renal physiology · 2024Article
- Editorial on the Special Issue "Advances in Pediatric Acute Kidney Injury".Children (Basel, Switzerland) · 2024Article
- Mouse models of sickle cell disease: Imperfect and yet very informative.Blood cells, molecules & diseases · 2024Review
- Machine Learning Predicts Acute Kidney Injury in Hospitalized Patients with Sickle Cell Disease.American journal of nephrology · 2024Article
- Epidemiology data on the cost and outcomes associated with pediatric acute kidney injury.Pediatric research · 2023Article
- Hemolysis scavenger proteins and renal function marker in children with sickle cell disease at steady state: A cross-sectional study.Health science reports · 2023Article
Corrections and comments
- Commented on by
Authors and funding
6 authors at 1 institution in 1 country.
Funding
Abstract
backgroundPatients who develop sickle cell disease (SCD) nephropathy are at a high risk for mortality. The pathophysiology of vaso-occlusive pain crisis may contribute to acute kidney injury (AKI). Non-steroidal anti-inflammatory drugs, known inducers of AKI, are used to treat pain crises. Multiple gaps exist in the knowledge about the impact of AKI in SCD.
methodsWe conducted a 2-year retrospective review of AKI events in patients admitted for vaso-occlusive crisis. AKI was defined by an increase of ≥0.3 mg/dL or 50% in serum creatinine from baseline. Laboratory values and ketorolac administration by days and dose (mg/kg) were identified from hospital records. A generalized mixed effects model for binary outcomes evaluated AKI based on laboratory variables and ketorolac administration. A generalized mixed Poisson effects model analyzed the association of AKI with hospital length of stay.
resultsThirty-three out of 197 admissions for vaso-occlusive pain crisis (17%) were associated with AKI. Fifty-two percent of the cases presented to the Emergency Room (ER) with AKI. Every one unit decrease in hemoglobin from baseline to admission increased the risk of AKI by 49%. Among patients who received ketorolac for pain, both total days and doses of ketorolac were associated with AKI. Finally, patients with pain and AKI required longer periods of hospitalization than patients without AKI.
conclusionAcute kidney injury during sickle cell pain crisis is common and may be an important modifiable risk factor for developing chronic kidney disease (CKD). Further studies are needed to determine the impact of nephrotoxic medications on progressive SCD nephropathy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.